Epidermal Growth Factor Receptor Market - Global Industry Analysis 2015 - 2019 and Opportunity Assessment; 2020 - 2030


Epidermal Growth Factor Receptor  Market
  • To Be Published : Dec-2020 |
  • Status : Work in progress |
  • Format : Epidermal Growth Factor Receptor  Market Epidermal Growth Factor Receptor  Market Epidermal Growth Factor Receptor  Market Epidermal Growth Factor Receptor  Market

Epidermal growth factor binds with protein is known as epidermal growth factor receptor protein. Epidermal growth factor receptor performs key role in signalling cell pathways to control cell division and survival. Mutations in epidermal growth factor receptor causes protein levels to fluctuate and impacts cell signalling. Reduced cell signalling leads to diseases like Alzheimer whereas over-expression causes cancer cells to divide more rapidly. Epidermal growth factor receptor market includes drugs that inhibits protein levels used in treatment of various types of cancers. According to the American Cancer Society (ACS), around 38.4% people are diagnosed with cancer at some point of life in the U.S.

There has been shift of focus among biopharmaceutical companies to develop coronavirus cure due to Covid-19. Delay of manufacturing activities and supply chain disruption will have short term negative impact on epidermal growth factor receptor market growth rate. Reduction in diagnosis and treatment adoption rate owing to decreased patient visits to healthcare facilities is expected to delay growth of epidermal growth factor receptor market.

Increasing prevalence of various types of cancer is expected to drive the growth of epidermal growth factor receptor market. Increasing collaborative research and development activities among leading biopharmaceutical innovative players is expected to fuel the growth of epidermal growth factor receptor market. In addition, clinical-stage development companies are allocating significant funds towards the development of the epidermal growth factor receptor market. For instance, in August 2020, the Daiichi Sankyo Company Limited and AstraZeneca announced clinical trial collaboration to evaluate an epidermal growth factor receptor tyrosine kinase inhibitor among patients with advanced EGFR mutation and metastatic non-small cell lung cancer. Stringent regulatory procedure for drug approval is expected to hinder growth of epidermal growth factor receptor market. Lower diagnosis rate is challenging factor for epidermal growth factor receptor market growth.

The global epidermal growth factor receptor market is classified based on drug type, route of administration, indication, distribution channel and region.

Based on drug type, the epidermal growth factor receptor market is segmented into the following:

  • Cetuximab
  • Panitumumab
  • Nimotuzumab
  • Gefitinib
  • Osimertinib

Based on the route of administration, the epidermal growth factor receptor market is segmented into the following:

  • Intraperitoneal
  • Intramuscular
  • Intravenous

Based on the indication, the epidermal growth factor receptor market is segmented into the following:

  • Lung Cancers
  • Colorectal Cancers
  • Breast Cancers
  • Others

Based on the distribution channel, the epidermal growth factor receptor market is segmented into the following:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drugstores
  • Online Pharmacies

Cetuximab and panitumumab generate major revenue share of epidermal growth factor receptor market. Intravenous drugs are most common and hold majority of revenue share in epidermal growth factor receptor market. Treatment of lung cancer with increased prevalence have high demand for epidermal growth factor receptor market. Whereas, colorectal cancer therapeutics is expected to observe exponential growth during forecast period. Hospital pharmacies is largest distribution channel followed by retail pharmacies of epidermal growth factor receptor market.

North America will continue to dominate the epidermal growth factor receptor market in the coming decade with a high rate of approvals and commercialization of pharmaceutical drugs. The high rate of prevalence of cancer increases the demand for epidermal growth factor receptor market in North America. Europe is the second leading region in epidermal growth factor receptor market with increased investments towards research and development activities. Asia-pacific is lucrative with a higher growth rate in the epidermal growth factor receptor market during the forecast period with a large patient population in the region. The Middle East and Africa are expected to observe the least growth in epidermal growth factor receptor market due to less healthcare expenditure in the region. Poor economic conditions in the Middle East and Africa make them untapped regions with fewer growth opportunities epidermal growth factor receptor market.

Some key players contributing in epidermal growth factor receptor market are Pfizer, Inc., Novartis AG, Hoffmann-La Roche Ltd, Amgen Inc., AstraZeneca plc., Eli Lilly and Company, Eisai, Inc., Bristol-Myers Squibb Company, Merck & Co., Johnson & Johnson, Biocon Ltd., Takeda Pharmaceutical Company, Daiichi Sankyo Company and others.

The report on epidermal growth factor receptor market covers exhaustive analysis on:

  • Market Segments
  • Market Dynamics
  • Historical Actual Market Size, 2015 - 2019
  • Market Size & Forecast 2020 to 2030
  • Supply & Demand Value Chain
  • Market Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain
  • Market Drivers and Restraints

Regional analysis for epidermal growth factor receptor market includes

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

 Report on epidermal growth factor receptor market highlights:

  • Shifting industry dynamics
  • In-depth market segmentation
  • Historical, current and projected industry size
  • Recent industry trends
  • Key competition landscape
  • Strategies of key players and product offerings
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance

Epidermal Growth Factor Receptor Market

Back To Top